The “microdosing” dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions
Journal of the American Association of Nurse Practitioners May 26, 2026 Nicole Trainer
ABSTRACT: The recent resolution of semaglutide and tirzepatide shortages by the US Food and Drug Administration (FDA) has fundamentally altered the regulatory landscape for compounded obesity medications. Despite recent federal pricing agreements to reduce GLP-1 costs, ongoing affordability barriers continue to drive patient desperation, fueling a shift toward unsupervised strategies such as...